Navigation Links
T-series (T70 DR, T60 DR, T20 SR )

ProductsT-series (T70 DR, T60 DR, T20 SR )
Company Vitatron B.V.
Item T-series (T70 DR, T60 DR, T20 SR )
Features 
  • Fast, for immediate insight
  • Digital, for ultimate accuracy
  • Freedom of choice in patient-focused therapies
    • Description Vitatron T-series is a new top-line range of digital pacemakers for the treatment of bradycardia and Atrial Fibrillation (AF). Because the T-series combines digital technology with unique solutions for AF, the treatment of AF is taken one step further. Thanks to the digital technology the heart rhythm is monitored continuously and extensively. This gives physicians the full picture of the patients condition at a glance, plus a wide choice in AF therapies. Vitatron T-series brings optimally individualized treatment and virtually symptom-free pacing.
    Info Vitatron B.V.
    Customer Service: +31 (0)26 376 7777
    Web site: http://www.vitatron.com/

    Related medicine products :

    1. Vivid 7
    2. Vivid i Cardiovascular Portable Ultrasound System
    3. Vivid i Cardiovascular Ultrasound System
    4. Vivid 4
    5. Vivid 3
    6. Vivid 3 CV Ultrasound System
    7. Vivid e
    8. Freshlook Dimensions
    9. Dimension AR IMT 110V/60HZ
    10. Dimension AR IMT 220V/50HZ
    11. Dimension RxL Max™ Integrated Chemistry System 50/60HZ
    TAG: series
    ...MiniCorr Digital Hand-Held Pulse Oximeter provides... neonate to adult. The device is battery or AC po...ible and audible alarm signals, and an infrared li...r boot is also available for added protection. Th...
    The FingerPrint Sleep Hand-Held Pulse Oximeter with built-in Summary Printer was specifically designed for sleep screening studies in the sleep lab, clinical environment, or home. With its easy-to-u
    The BCI 3180 Pulse Oximeter is a cost-effective, stand-alone monitor that delivers fast, reliable SpO 2 pulse rate and pulse strength measurements of patients from neonate to adult. This AC or batt
    ...U.S. Food and Drug Administration (FDA) has grante...ens (IOL) for cataract patients with and without p...ry apodized diffractive technology to give patient...te and distance) that greatly increases their inde...
    Medicine Products:
    (Date:10/14/2008)... Also debuts TMR,09 campaign, IRVINE, Calif., O...poration (Pink Sheets: CGCP), a global leader of i...nd the market leader of surgical products for,tran...educational symposium,yesterday in conjunction wit...rapeutics (TCT) meeting in Washington, D.C., The ...
    (Date:10/14/2008)... more than 500 accounts Company opening new PROMUS...ICK, Mass., Oct. 14 /PRNewswire-FirstCall/ -- Bost...unced estimated U.S. market shares for,September f...liminary data,from Millennium Research Group (MRG)...he healthcare sector., Based on the MRG data, the...
    (Date:10/14/2008)... Leading Supplemental Insurance Company Encour... Employee Benefits , Chic...e , a leading provider of supplemental insurance, ...time to review employee benefits and recommends ,V...to help retain employees. These programs can be a ...
    (Date:10/14/2008)...ctober 14 /PRNewswire/ -- Researchers at the Insti... started work on a 3.5 year,project to develop a n...hemical vapour deposition) diamond manufactured by...he field of CVD diamond synthesis and its,applicat...uld open up a raft of new,application areas in, fo...
    Breaking Medicine News(10 mins):Health News:Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C. 2Health News:Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C. 3Health News:Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C. 4Health News:Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter 2Health News:Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter 3Health News:Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September and Third Quarter 4Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 2Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 3Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 4Health News:Combined Insurance Reports that Voluntary Programs Can Offer Employers a Cost Effective Way to Offer Benefits and Help Retain Employees 5Health News:Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications 2Health News:Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications 3Health News:Novel Solid-State Laser Design Based on Synthetic Diamond From Element Six Opens up New Applications 4
    ...r to shut down the neo-natal intensive care unit o...l with immediate //effect was passed by the Philip...g reports of the death of seven new born babies. ...bies have been certified by the hospital to have o...
    ...tatistics show a phenomenal rise in sexually trans... Chlamydia one of the most common treatable sexua...e, is now reported to have increased four-fold in ...n subcontinent. with new cases having been reporte...
    ...k: Hookah is dangerous, more so because its look a...st acquired a ‘cult’ status, and is becoming the l...ngton has warned that the hookah or the pipe is in... Christopher Loffredo, director of the Cancer Gene...
    ...ople with dengue symptoms have been admitted to a ...t the Soura Institute of Medical Sciences Thursday...of the institute. "The samples of two of the four...tive, ruling out fear of the dreaded fever," a sen...
    Other Medicine News:Health News:Sexually Transmitted Diseases Soaring Due To Unsafe Sex 2
    (Date:10/14/2008)... Additional Data Presentation Shows Encouraging ...ving Patients with Predominantly Complex Lesions, ...day announced that an,interim analysis of 12-month... show good safety and efficacy in the real-world u..., Presented by Professor Robbert de Winter, M.D.,...
    (Date:10/13/2008)... New Analysis of SPIRIT II and SPIRIT III Data Co...r Risk of Experiencing Death, a Heart Attack or a ... Two Years, WASHINGTON, Oct. 13 /PRNewswire-First... Abbott,s SPIRIT II and SPIRIT III randomized clin...rolimus Eluting Coronary Stent,System continues to...
    (Date:10/13/2008)... FirstVue(TM) HBSAG Test Found to Have Higher Sen...Tests and FirstVue(TM) ,...and was the preferred ...on, CORAL SPRINGS, Fla., Oct. 13 /-...keting leader in rapid diagnostic test kits, today...he Walter Reed Army,Institute of Research of the F...
    (Date:10/13/2008)... HOPKINTON, Mass., Oct. 13 /- Face...f 6 month follow-up on 20 patients from its US,IDE...Oswestry Disability,Index (ODI) scores, and an 80%...omatic leg pain. Geoff Pardo, President & CEO for ...these early results, which thus far not,only demon...
    Breaking Medicine Technology:Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 2Interim Analysis of 12-Month Data from e-HEALING Registry Shows Good Safety and Efficacy in Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) 3Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 2Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 3Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 4Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 5Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 2Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 3Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 4Weight gain related to postmenopausal breast cancer risk 4302 1Weight gain related to postmenopausal breast cancer risk 4302 2Fighting obesity may be as easy as ATP says UH researcher 4299 1Fighting obesity may be as easy as ATP says UH researcher 4299 2Fighting obesity may be as easy as ATP says UH researcher 4299 3Saks Fifth Avenue Unveils Five Magical Holiday Gifts 4296 1Saks Fifth Avenue Unveils Five Magical Holiday Gifts 4296 2Saks Fifth Avenue Unveils Five Magical Holiday Gifts 4296 3This October the American Physical Therapy Associations National Physical Therapy Month to Focus on Nations Obesity Epidemic 4293 1This October the American Physical Therapy Associations National Physical Therapy Month to Focus on Nations Obesity Epidemic 4293 2This October the American Physical Therapy Associations National Physical Therapy Month to Focus on Nations Obesity Epidemic 4293 3This October the American Physical Therapy Associations National Physical Therapy Month to Focus on Nations Obesity Epidemic 4293 4
    ...ESS WIRE)--Apr 16, 2007 - Arsenic, a naturally,occ...unds for over,2,000 years, and even now remains a ...harmacopeia., Today, due in measure to the efforts...uel Waxman Cancer Research Foundation,s,(SWCRF) "I...being,utilized in therapy for the treatment of cer...
    ...SINESS WIRE)--Apr 17, 2007 - ProNAi Therapeutics,... class of,nucleic-acid drugs based on DNA interfer...y therapeutic candidate, PNT2258,has successfully...graft mice for a number of human cancers - includi...s Lymphoma., Dr. Richard D. Gill, President and CE...
    Other Medicine Technology:Research Supported by Samuel Waxman Cancer Research Foundation,Discovers Mode of Action of Arsenic-Based Drugs in Destroying,Cancer Cells 2Research Supported by Samuel Waxman Cancer Research Foundation,Discovers Mode of Action of Arsenic-Based Drugs in Destroying,Cancer Cells 3ProNAi Announces Preclinical Success for PNT2258 Therapeutic -,Curative Events in Xenograft Mice for Difficult-to-Treat,Non-Hodgkin's Lymphoma 2